When tumors reached 100-300mm3 in volume, animals were randomized into the following treatment groups: one group received the murine surrogate CEA-targeted T cell bi-specific antibody (CEA-TCB), which simultaneously binds to the CEA protein on cancer cells and CD3 on T cells and elicits a T cell mediated attack on CEA-expressing tumors, independent of T cell receptor specificity (50, 79); one group was treated with the checkpoint inhibitor, anti-PD-L1 (aPD-L1), and a third group was treated with the combination of CEA-TCB and aPD-L1 antibody. Here, CD274 is linked to cancer.